- Molecular NameFlurbiprofen
- SynonymFLP; Flurbiprofen Sodium; Flurbiprofene [INN-French]; Flurbiprofeno [INN-Spanish]; Flurbiprofenum [INN-Latin]
- Weight244.265
- Drugbank_IDDB00712
- ACS_NO5104-49-4
- Show 2D model
- LogP (experiment)4.16
- LogP (predicted, AB/LogP v2.0)3.95
- pka4.2
- LogD (pH=7, predicted)1.25
- Solubility (experiment)0.008 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-1.12
- LogSw (predicted, AB/LogsW2.0)0.02
- Sw (mg/ml) (predicted, ACD/Labs)0.06
- No.of HBond Donors1
- No.of HBond Acceptors2
- No.of Rotatable Bonds3
- TPSA37.3
- StatusFDA approved
- AdministrationN/A
- PharmacologyA member of the phenylalkanoic acid derivative family of non-steroidal anti-inflammatory drugs (NSAIDs) used to treat the inflammation and pain of arthritis.
- Absorption_value95.0
- Absorption (description)Readily absorbed after oral administration.
- Caco_2N/A
- Bioavailability92.0
- Protein binding99.5
- Volume of distribution (VD)0.1 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic (CYP2C9)
- Half life3.5 h
- ExcretionAbout 95% of a dose is excreted in the urine in 24 h, mainly as the 4′-hydroxy, 3′,4′-dihydroxy, and 4′-methoxy metabolites, which are excreted partly as conjugates; about 25% of a dose is excreted as unchanged drug.
- Urinary ExcretionN/A
- Clerance0.3 ml/min/kg
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A